Platinum Chemotherapy Vs. Capecitabine In Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Posted Date: Sep 25, 2019
- Investigator: Neetu Radhakrishnan
- Specialties: Breast Cancer, Cancer
- Type of Study: Drug
This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.
Criteria:
Residual Disease In Breast ( After Chemotherapy) Of 1Cm Or More
Keywords:
Triple Negative Breast Cancer Stage 2 Or 3, Residual Disease After Chemotherapy, After Neoadjuvant Chemotherapy
For More Information:
Laura Bundus
5135847847
bundusla@ucmail.uc.edu